REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron Pharmaceuticals, Inc. (REGN) reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea HD sales, profits from blockbuster asthma drug Dupixent and oncology drug Libtayo. The top line beat the Zacks Consensus Estimate of$3.67 billion.Higher revenues drove the bottom line as well. Adjusted earnings per share (EPS) of $12.46 beat the Zacks Consensus Estimate of$11.75 and were up 8% from the yea ...